Abstract:4933 The chemotherapy of advanced hormone refractory prostate cancer is severely compromised by drug resistance and dose limiting toxicity. Here we tested whether selenium could enhance the apoptosis potency of selected chemotherapeutic drugs in DU145 and PC3 human androgen-independent prostate cancer cells. Exponentially growing cells were exposed to low doses of selenium and/or the topoisomerase I poison 7-ethyl-10-hydroxycamptothecin (SN38), the topoisomerase II inhibitor etoposide or the microtubule drug paclitaxel/taxol. Apoptosis was measured by ELISA for histone-associated DNA fragments, by flow cytometric analysis of sub-G1 fraction, and by immunobloting the caspase cleaved poly(ADP-ribose)polymerase. Our results show that the methylselenol precursor methylseleninic acid (MSeA) increased the apoptosis potency of SN38, etoposide or paclitaxel by several folds higher than the expected sum of the apoptosis induced by MSeA and each drug alone in both cell lines. Mechanistically, the combination treatment did not further enhance the phosphorylation of c-Jun N-terminal kinase (JNK)1/2 that was induced by each drug in DU145 cells. The JNK inhibitor SP600125 substantially decreased the activation of caspases and apoptosis induced by MSeA combination with the drugs. The caspase-8 inhibitor zIETDfmk completely abolished apoptosis and caspase-9 and caspase-3 cleavage, whereas the caspase-9 inhibitor zLEHDfmk significantly decreased caspase-3 cleavage and apoptosis but had no effect on caspase-8 cleavage. None of these caspase inhibitors abolished JNK1/2 phosphorylation. In contrast to MSeA, selenite did not show any enhancing effect on the apoptosis induced by these drugs. In conclusion, MSeA enhanced apoptosis induced by cancer therapeutic drugs in DU145 cells primarily through interactions between MSeA and JNK-dependent targets to amplify what appeared to be a caspase-8-initiated activation cascade. The results suggest, to our knowledge, for the first time a novel use of methyl selenium for improving the chemotherapy of prostate cancer. Grant supports: CA92231 and CA95642 from NCI and DAMD17-02-1-0007 from DOD.

Selenocysteine Derivative Overcomes TRAIL Resistance in Melanoma Cells: Evidence for ROS-dependent Synergism and Signaling Crosstalk.

1,4-Diselenophene-1,4-diketone Triggers Caspase-Dependent Apoptosis in Human Melanoma A375 Cells Through Induction of Mitochondrial Dysfunction

Selenocystine Potentiates Cancer Cell Apoptosis Induced by 5-Fluorouracil by Triggering Reactive Oxygen Species-Mediated DNA Damage and Inactivation of the ERK Pathway

Sensitization of Cancer Cells to Radiation by Selenadiazole Derivatives by Regulation of ROS-mediated DNA Damage and ERK and AKT Pathways.

Seleno-cyclodextrin sensitises human breast cancer cells to TRAIL-induced apoptosis through DR5 induction and NF-κB suppression.

Selenadiazole Derivatives As Theranostic Agents for Simultaneous Cancer Chemo-/Radiotherapy by Targeting Thioredoxin Reductase

Selenadiazole Derivatives As Potent Thioredoxin Reductase Inhibitors That Enhance the Radiosensitivity of Cancer Cells

Synergistic Induction of Apoptosis by Methylseleninic Acid and Cisplatin, the Role of ROS-ERK/AKT-p53 Pathway

Inorganic Selenium Sensitizes Prostate Cancer Cells to TRAIL-induced Apoptosis Through Superoxide/p53/bax-Mediated Activation of Mitochondrial Pathway

Dual-functional Se/Fe Complex Facilitates TRAIL Treatment Against Resistant Tumor Cells Via Modulating Cellular Endoplasmic Reticulum Stress

Selenocystine Induces Reactive Oxygen Species-Mediated Apoptosis in Human Cancer Cells

Anti-recurrence/metastasis and chemosensitization therapy with thioredoxin reductase-interfering drug delivery system

Strategy to Enhance the Therapeutic Effect of Doxorubicin in Human Hepatocellular Carcinoma by Selenocystine, A Synergistic Agent That Regulates the Ros-Mediated Signaling

Enhancement of Auranofin-Induced Apoptosis in MCF-7 Human Breast Cells by Selenocystine, a Synergistic Inhibitor of Thioredoxin Reductase

Selenocystine Induces Caspase-Independent Apoptosis in MCF-7 Human Breast Carcinoma Cells with Involvement of P53 Phosphorylation and Reactive Oxygen Species Generation.

Selenomethionine-Conjugated Extracellular Vesicles for ROS-Mediated Cell Apoptosis

Mitochondria-mediated apoptosis in human breast carcinoma MCF-7 cells induced by a novel selenadiazole derivative.

Methylseleninic acid potentiates apoptosis induced by chemotherapeutic drugs in prostate cancer cells through enhancing caspase activation

Nutritional Available Seleno-amino Acid Derivative Antagonizes Cisplatin-induced Nephrotoxicity Through Inhibition of ROS-mediated Signaling Pathways.

Breaking the Intracellular Redox Balance with Diselenium Nanoparticles for Maximizing Chemotherapy Efficacy on Patient-Derived Xenograft Models

Docosahexaenoic Acid Coordinating with Sodium Selenite Promotes Paraptosis in Colorectal Cancer Cells by Disrupting the Redox Homeostasis and Activating the MAPK Pathway